CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, Ouji N, Yamada S, Nakagawa I, Park YS, et al. J Exp Clin Cancer Res. 2023 Aug 10; 42(1):205. Epub 2023 Aug 10.